|
[posting]59931692[/posting]28.2. http://investors.akorn.com/news-releases/news-release-detail… => Fourth Quarter 2018 and Recent Business Highlights • Net revenue was $153 million, a decline of $33 million, or 17.6%, compared to the fourth quarter of 2017, predominantly due to the effect of competition on key products and shortfalls in supply • Net loss was $215 million compared to a net loss of $65 million in the fourth quarter of 2017. Adjusted EBITDA was $(20) million compared to $28 million in the fourth quarter of 2017 • Continued progress on completion of FDA action items related to the inspections of our facilities in Decatur and Somerset • Appointed Douglas Boothe as President and Chief Executive Officer, bringing significant generic and specialty pharmaceutical leadership experience • Announced new additions to Board of Directors and Executive Management team adding significant expertise to the Company’s leadership • Focused on moving forward and rebuilding shareholder value as an independent company following the terminated Fresenius Kabi AG merger agreement • Engaged financial, operational, and legal advisors to help develop and execute long-term growth plan • Healthy cash position of $225 million as of December 31, 2018 |
|
| aus der Diskussion: | ANALYSE: Akorn-Aktie möglicherweise vor noch größerem Absturz - Raymond James |
| Autor (Datum des Eintrages): | faultcode (28.02.19 20:24:27) |
| Beitrag: | 96 von 146 (ID:59989915) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |